drugset / Trial / NCT05156398

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

NCT05156398

Phase 3 Recruiting 640 enrolled Pfizer
RandomizedSequentialQuadruple-blindPrevention

Summary

The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine.

Timeline

Start
2022-02-28
Primary completion
2031-11-29
Completion
2032-11-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rimegepant Small molecule 50 mg Oral
Comparator Rimegepant Small molecule 75 mg Oral

Indications